NASDAQ$ALNY
Alnylam Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Alnylam reported strong commercial execution and pipeline advancements.
Alnylam Pharmaceuticals reported Q4 2022 financial results, with global net product revenues reaching $262 million, contributing to a full-year revenue of $894 million, a 35% increase compared to 2021. The company highlighted the acceptance of its sNDA for ONPATTRO and provided 2023 combined net product revenue guidance of $1,200 million to $1,285 million.
- Global net product revenues for Q4 2022 reached $262 million, and full-year revenues reached $894 million, representing a 35% annual growth compared to 2021.
- The sNDA for ONPATTRO for the treatment of the cardiomyopathy of ATTR amyloidosis submitted and accepted.
- Combined net product revenue guidance for 2023 is projected to be between $1,200 million and $1,285 million.
- AMVUTTRA launch has demonstrated a great start in its first two full quarters on the market.
Headline financials
Revenue & EPS history
Alnylam · Revenue · Quarterly
$335M
Revenue by segment
Alnylam · $262M total across 4 segments · Q4 2022
- ONPATTRO$122M-11.8%46.7%
- AMVUTTRA$68.6M—26.2%
- GIVLAARI$47.1M+15.7%18.0%
- OXLUMO$23.8M+24.1%9.1%
Forward guidance
Alnylam anticipates combined net product revenues between $1,200 million and $1,285 million for 2023, along with revenues from collaborations and royalties between $100 million and $175 million. The company projects GAAP R&D and SG&A expenses between $1,790 million and $1,885 million, and non-GAAP R&D and SG&A expenses between $1,575 million and $1,650 million.
Tailwinds
- Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021
- Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO are expected to be between $1,200 million and $1,285 million for full year 2023.
- Net Product Revenue Growth vs. 2022 at reported Fx rates is expected to be 34% to 44% for full year 2023.
- Net revenues from collaborations and royalties are expected to be between $100 million – $175 million for full year 2023.
- Submitted and Received Acceptance of Supplemental New Drug Application (sNDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Headwinds
- GAAP R&D and SG&A expenses are expected to be between $1,790 million – $1,885 million for full year 2023.
- Non-GAAP R&D and SG&A expenses are expected to be between $1,575 million – $1,650 million for full year 2023.
- Assumes U.S. sNDA approval of patisiran for ATTR amyloidosis with cardiomyopathy by the PDUFA date on October 8, 2023.
- Excludes $215-$235 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+15.4%
Q2 2025
Best reaction
-16.9%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.0% | +0.2% | |
| Q4 2025 | -4.3% | +3.2% | -2.8% | |
| Q3 2025 | -6.7% | -12.1% | -6.3% | |
| Q2 2025 | +15.4% | +23.3% | +31.4% | |
| Q1 2025 | -3.1% | +2.5% | +15.7% | |
| Q4 2024 | -0.4% | -6.0% | -9.1% | |
| Q3 2024 | -2.7% | -5.8% | -10.1% | |
| Q2 2024 | +14.6% | +10.6% | +10.6% | |
| Q1 2024 | +1.6% | +2.9% | -1.0% | |
| Q4 2023 | -10.4% | -8.8% | -9.1% | |
| Q3 2023 | +6.6% | +8.4% | +9.2% | |
| Q2 2023 | -0.8% | -1.2% | +7.6% | |
| Q1 2023 | +6.3% | +4.2% | -2.9% | |
| Q4 2022 | -5.6% | -4.8% | -5.5% | |
| Q3 2022 | +1.7% | +6.0% | +5.8% | |
| Q2 2022 | +0.0% | +0.0% | +48.6% | |
| Q1 2022 | -13.9% | -7.8% | -17.5% | |
| Q4 2021 | -0.4% | +1.3% | +2.4% | |
| Q3 2021 | -16.5% | -12.3% | -1.4% | |
| Q2 2021 | +3.1% | +9.7% | +12.5% | |
| Q1 2021 | -2.0% | -8.3% | -1.1% | |
| Q4 2020 | -3.8% | -6.3% | -13.4% | |
| Q3 2020 | -6.3% | -10.4% | -7.1% | |
| Q2 2020 | -4.6% | -9.2% | -18.4% | |
| Q1 2020 | +0.2% | +0.8% | -9.7% | |
| Q4 2019 | +3.2% | +6.5% | -6.7% | |
| Q3 2019 | +4.3% | +5.5% | +34.2% | |
| Q2 2019 | +12.7% | +13.1% | +16.4% | |
| Q1 2019 | -7.6% | -17.1% | -24.4% | |
| Q4 2018 | -5.0% | +2.5% | +1.8% | |
| Q3 2018 | -15.3% | -21.3% | -13.8% | |
| Q2 2018 | -3.0% | -0.6% | +29.8% | |
| Q1 2018 | +2.6% | +6.8% | +11.8% | |
| Q4 2017 | -5.1% | -2.3% | +9.0% | |
| Q3 2017 | +1.4% | +7.3% | -1.4% | |
| Q2 2017 | -6.8% | -2.2% | -9.5% | |
| Q1 2017 | -4.1% | +1.5% | +31.2% | |
| Q4 2016 | +11.1% | +12.7% | +25.4% | |
| Q3 2016 | -15.1% | -2.0% | +12.4% | |
| Q2 2016 | +9.9% | +7.1% | -3.1% | |
| Q1 2016 | -9.3% | — | — | |
| Q4 2015 | +4.5% | — | — | |
| Q3 2015 | +5.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +6.7% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +3.2% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +5.3% | — | — | |
| Q4 2013 | -2.1% | — | — | |
| Q3 2013 | -11.2% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.5% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -1.5% | — | — | |
| Q1 2012 | -9.0% | — | — | |
| Q4 2011 | -9.6% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q2 2011 | -14.9% | — | — | |
| Q1 2011 | +2.3% | — | — | |
| Q4 2010 | +13.2% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -0.9% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro